No description available.

Alternatives mRNA-Splicing ist ein häufig beobachtetes Phänomen, das es der Zelle ermöglicht, unterschiedliche Proteine aus einem Gen zu generieren. In den letzten Jahren wurden immer mehr alternativ gespleißte Transkripte entdeckt, und einigen der daraus resultierenden Protein-Isoformen konnten geänderte biologische Funktionen zugeordnet werden. In dieser Arbeit ist erstmals ein alternativ gespleißtes Transkript der Interleukin-4 Rezeptor alpha (IL-4R-alpha) Kette beschrieben. Dieser mRNA Splice-Variante, genannt IL-4R-alpha-IT, fehlt im membranproximalen Bereich der zytoplasmatischen Domäne ein komplettes Exon. Dies führt zur Verschiebung des Leserasters und so zur Entstehung eines vorzeiten Stop-Codons. Der resultierenden Protein-Isoform fehlt der größte Teil der intrazellulären Kette mit den dort enthaltenen, für die Signaltransduktion essentiellen Domänen. Die Untersuchung der biologischen Funktion der Rezeptor-Varianten in einem geeigneten Zellsystem der Maus zeigte, daß die Splice-Variante IL-4R-alpha-IT keine Proliferation der Zellen vermitteln und auch den Übergang der Zellen in die Apoptose nicht verhindern kann. Bei der Quantifizierung der Expression von IL-4R-alpha-IT-mRNA in Relation zum IL-4R-alpha voller Länge mit einer kompetitiven RT-PCR an Knochenmark und peripheren Blutlymphozyten von Kindern mit ALL zeigte sich zunächst ein irreführender Unterschied zwischen Proben von Kindern mit ALL-Ersterkrankung und Rezidiv. Weitere Untersuchungen ergaben jedoch, daß der Zeitraum zwischen Abnahme und Aufarbeitung des Untersuchungsmaterials für diesen scheinbaren Zusammenhang verantwortlich war. Während direkt nach Abnahme aufgearbeitetes Untersuchungsmaterial eine nur niedrige relative Expression der Splice-Variante zeigte, nahm diese bei verzögerter Aufarbeitung drastisch zu. Diese Beobachtung wurde experimentell an Proben gesunder Probanden wiederholt bestätigt. Interessanterweise konnte derselbe Effekt in unterschiedlicher Ausprägung auch bei Splice-Variante anderer Zytokine und -Rezeptoren wie IL-7, IL-7R und beta-C beobachtet werden. mRNA-Stabilitäts-Assays und die Bestimmung der einzelnen Transkripte mit einer semiquantitativen RT-PCR zeigten, daß es tatsächlich zu einer absoluten Hochregulation der IL-4R-alpha-IT-mRNA in den verzögerte aufgearbeiteten Proben kommt. Wurden die Zellen wieder in Kultur genommen, war dies innerhalb weniger Stunden reversibel. Desweiteren scheinen auch unterschiedlichen mRNA-Stabilitäten eine Rolle zu spielen. / Alternative pre-mRNA splicing is a widespread mechanism contributing to the diversity of gene expression. The number of newly detected alternatively spliced transcripts has continuously risen, and distinct biological functions have been attributed to some protein isoforms resulting from these mRNA variants. We report on the detection of a novel alternatively spliced transcript of the human interleukin-4 receptor alpha (IL-4R-alpha) chain, which has been called IL-4R-alpha-IT mRNA. A premature stop codon due to omission of one exon in the membrane-proximal region of the cytoplasmic domain leads to an mRNA variant, which encodes an intracellular truncated receptor protein lacking domains which are essential for signal transduction. The investigation of the biological function of the IL-4Ra splice variants in a suitable mouse cell system showed, that the truncated receptor variant is not able to mediate cell proliferation or prevention of apoptosis. Bone marrow and peripheral blood samples from children with acute lymphoblastic leukemia were analyzed for the expression of IL-4R-alpha-IT mRNA relative to the full-length receptor transcript by competitive RT-PCR. Initially, there was found a difference of IL-4R-alpha-IT mRNA expression in patients with initial ALL versus relapsed ALL. However, this difference turned out to be due to the time interval between collection and preparation of samples. While freshly isolated material was associated with low levels of IL-4R-alpha-IT mRNA, samples with a longer period until cell preparation exhibited a drastic increase of IL-4R-alpha-IT mRNA levels. The same results were obtained for peripheral blood samples from healthy donors by imitating a prolonged time of transport until cell preparation. Interestingly, a similar effect could be demonstrated for splice variants of other cytokine receptors and cytokines (beta-C, IL-7R, and IL-7), although to different extents. mRNA stability assays and semiquantitative RT-PCR specific for IL-4Ra or IL-4R-alpha-IT, respectively, indicated that the expression of IL-4R-alpha-IT mRNA increases absolutely in these samples, although mRNA degradation may be of importance as well.

A plethora of naturally-produced steroid hormones, or artificial homologues of them, are being introduced into the aquatic and terrestrial environments each year. Two examples of these are the natural oestrogen 17-oestradiol (E2) and the oestrogen receptor antagonist, Bisphenol A (BPA), both of which target the ribonucleoprotein telomerase through upregulation of its telomerase reverse transcriptase component, TERT. The main objectives of this study were firstly to isolate and characterize the actual mRNA sequence for the telomerase catalytic subuninit, Tert, in rainbow trout (Oncorhynchus mykiss) (Walbaum, 1792) and European purple sea urchin (Paracentrotus lividus) (Lamarck, 1816), with the aim of developing qPCR assays for the amplification and quantification of Tert. Further objectives were to use these assays in controlled exposure studies to establish whether and to what extent the aforementioned chemicals regulate Tert transcription and by doing so further understand the mechanism of Telomerase gene expression and the extent to which environmental oestrogen can interfere. The initial step of sequence characterization and assay devlopment was successful in the case of rainbow trout where two possible splice variants of Tert mRNA are identified, omTertShort and omTertLong. Two qPCR assays were developed for the relative quantification of both of these splice variants in rainbow trout samples, the latter of these successfully amplifying its target in test samples. In order to demonstrate in vitro and in vivo modulation of telomerase activity and mRNA expression, early life-stages of rainbow trout and purple sea urchin, as well as rainbow trout hepatocytes, were exposed to a range of concentrations of E2 and BPA. Purple sea urchin embryos were exposed to 200, 20 and 2 ng E2/ml for 28 hours until they had reached the stage of pluteus larvaes. Rainbow trout embryos were exposed to 500, 20 and 0.1 ng E2/ml and 600 and 150 ng BPA/ml for 167 days from immediately after fertilization. Rainbow trout hepatocytes were exposed to 20 and 2 ng E2/ml for 48 hours. The results from this study show that telomerase activity as well as TERT mRNA expression can be significantly modulated by exposure to oestrogens and other oestrogenic chemicals. E2 concentrations as low as 20 ng/ml lead to an increase in telomerase activity early-life stages of purple sea urchin and upregulation in the transcription of Tert mRNA in unhatched rainbow trout embryos. BPA induced similar response (600 ng/ml) in hatched rainbow trout alevins larvae. Very high exposures to E2 (500 ng/ml) do however lead to downregulation of Tert mRNA in hatched alevins larvae. Differential regulatory response can be observed between different tissue types of 167 day old fry, with an upregulatory response observed at 0.1 ng E2/ml in liver and muscle tissues, but not in brain. Similarly, brain tissues were observed expressing significantly less mRNA than liver and muscle samples when exposed to BPA (150 ng/ml). It is evident that the previously observed link between environmental oestrogens and telomerase is also present in the two test species examined; purple sea urchin and rainbow trout.

Dans cette thèse, l’impact du polymorphisme rs3846662 sur l’épissage alternatif de la 3-hydroxy-3-méthylglutaryl coenzyme A réductase (HMGCR) a été investigué in vivo, chez des patients atteints d’hypercholestérolémie familiale (HF) ou de maladie d’Alzheimer (MA). Le premier manuscrit adresse la problématique de la normalisation de la quantification relative des ARNm par PCR quantitative. Les découvertes présentées dans ce manuscrit nous ont permis de déterminer avec un haut niveau de confiance les gènes de référence à utiliser pour la quantification relative des niveaux d’ARNm de l’HMGCR dans des échantillons de sang (troisième manuscrit) et de tissus cérébraux post-mortem (quatrième manuscrit). Dans le deuxième manuscrit, nous démontrons grâce à l’emploi de trois cohortes de patients distinctes, soit la population canadienne française du Québec et les deux populations nord américaines « Alzheimer’s Disease Cooperative Study (ADCS) » et « Alzheimer’s Disease Neuroimaging Initiative (ADNI) », que le génotype AA au locus rs3846662 confère à ces porteurs une protection considérable contre la MA. Les femmes porteuses de ce génotype voient leur risque de MA diminuer de près de 50% et l’âge d’apparition de leurs premiers symptômes retarder de 3.6 ans. Les porteurs de l’allèle à risque APOE4 voient pour leur part leurs niveaux de plaques séniles et dégénérescences neurofibrillaires diminuer significativement en présence du génotype AA. Enfin, les individus atteints de déficit cognitif léger et porteurs à la fois de l’allèle APOE4 et du génotype protecteur AA voient leur risque de convertir vers la MA chuter de 76 à 27%. Dans le troisième manuscrit, nous constatons que les individus atteints d’HF et porteurs du génotype AA ont, contrairement au modèle établi chez les gens normaux, des niveaux plus élevés de cholestérol total et de LDL-C avant traitement comparativement aux porteurs de l’allèle G. Le fait que cette association n’est observée que chez les non porteurs de l’APOE4 et que les femmes porteuses du génotype AA présentent à la fois une augmentation des niveaux d’ARNm totaux et une résistance aux traitements par statines, nous indique que ce génotype influencerait non seulement l’épissage alternatif, mais également la transcription de l’HMGCR. Comme une revue exhaustive de la littérature ne révèle aucune étude abondant dans ce sens, nos résultats suggèrent l’existence de joueurs encore inconnus qui viennent influencer la relation entre le génotype AA, l’épissage alternatif et les niveaux d’ARNm de l’HMGCR. Dans le quatrième manuscrit, l’absence d’associations entre le génotype AA et les niveaux d’ARNm Δ13 ou de protéines HMGCR nous suggère fortement que ce polymorphisme est non fonctionnel dans le SNC affecté par la MA. Une étude approfondie de la littérature nous a permis d’étayer cette hypothèse puisque les niveaux de HNRNPA1, la ribonucléoprotéine influencée par l’allèle au locus rs3846662, sont considérablement réduits dans la MA et le vieillissement. Il est donc proposé que les effets protecteurs contre la MA associés au génotype AA soient le résultat d’une action indirecte sur le processus physiopathologique. / In this thesis, the impact of rs3846662 polymorphism on the alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) was investigated in vivo, in patients with familial hypercholesterolemia (FH) or Alzheimer disease (AD). The first manuscript addresses the issue of normalization in relative quantification of mRNA by quantitative PCR. The findings presented in this manuscript have allowed us to determine with a high level of certainty the appropriate reference genes to use for the relative quantification of HMGCR mRNA levels in blood samples (third manuscript) and postmortem brain tissues (fourth manuscript). In the second manuscript, we demonstrate through the use of three independent cohorts, namely the French Canadian population of Quebec and the two North American populations named "Alzheimer's Disease Cooperative Study (ADCS)" and "Alzheimer's Disease Neuroimaging Initiative (ADNI) ", that the AA genotype at locus rs3846662 confers significant protection against AD. Women carrying this genotype decrease their risk of AD by about 50%, and delay their age of onset of 3.6 years. For their part, individuals carrying both the APOE4 risk allele and the AA genotype have decreased levels of senile plaques and neurofibrillary tangles compared to individuals carrying both the APOE4 and HMGCR G alleles. Finally, individuals suffering from mild cognitive impairment and carrying both the APOE4 risk allele and the protective AA genotype see their risk of converting to AD drop from 76% to 27%. In the third manuscript, contrary to the model described in normal subjects, we discovered that individuals with FH carrying the AA genotype have higher levels of total cholesterol and LDL-C before treatment compared to the carriers of the G allele. This latter association is observed only in non-carriers of the APOE4 risk allele. Furthermore, women carrying the AA genotype have both an increase in total HMGCR mRNA levels and a decrease response to statin treatment. These results suggest the AA genotype has an impact not only on the alternative splicing, but also on the transcription of HMGCR. Since an exhaustive review of the literature has reveal no studies corroborating this hypothesis, our results suggest the existence of yet unknown players influencing the relationships between the AA genotype, alternative splicing and the mRNA levels of HMGCR. In the fourth manuscript, we uncovered no association between the AA genotype and Δ13 mRNA or HMGCR protein levels. This strongly suggests that the rs3846662 polymorphism is not functional in the CNS affected by AD. A thorough study of the literature enabled us to support this hypothesis since the levels of HNRNPA1, the ribonucleoprotein influenced by the allele status at rs3846662 locus, are significantly reduced in AD and aging. Accordingly, we propose that the protective effects of the AA genotype against AD may be mediated through indirect effects on the physiopathology of the disease.

La régulation de l’expression des gènes est fondamentale pour coordonner la synthèse, l’assemblage et la localisation des complexes macromoléculaires dans les cellules. Cette expression est régulée à divers niveaux. Elle commence dans le noyau où les facteurs de transcription se lient à des séquences spécifiques d’ADN et recrutent les ARN polymérases pour la synthèse des ARN. La régulation à ce niveau est dite transcriptionnelle. Les protéines de liaison à l’ARN s’associent avec l’ARN en cours de synthèse et opèrent divers modifications comme l’addition d’une coiffe en 5’, l’épissage, l’édition et la poly-adénylation en 3’. Les transcrits sont alors exportés vers le cytoplasme où ils vont être adressés et stockés dans des régions subcellulaires. Les ARNm s’assemblent avec des facteurs de traduction et les ribosomes pour initier la synthèse protéique de manière contrôlée. Enfin, les ARNm sont dégradés. Les régulations qui touchent chacune de ces étapes sont dites post-transcriptionnelles. Le développement récent d’outils d’analyse à l’échelle génomique ont permis une meilleure compréhension globale des programmes de régulation des gènes au niveau transcriptionnel. Cependant, l’architecture globale des systèmes qui régulent les étapes post-transcriptionnelles d’expression des gènes est encore peu connue. Un tel système de régulation post-transcriptionnelle doit être contrôlé par des centaines de protéines de liaison à l’ARN et de microARN (miARN) encodés dans les génomes eucaryotes. C’est pourquoi il est important de disposer d’outils et de plateformes adaptés à l’étude de cette régulation à l’échelle génomique. Dans cette thèse, nous nous sommes intéressés à deux programmes de la régulation post-transcriptionnelle chez Caenorhabditis elegans : l’épissage alternatif et la régulation par les miARN. Nous avons utilisés des vers rapporteurs de l’épissage alternatif exprimant la double fluorescence GFP et RFP afin d’étudier l’architecture de cette régulation et l’identification ou la validation des facteurs en trans et des éléments en cis par génétique classique en utilisant la mutagenèse aléatoire, l’automatisation du crible grâce au COPAS biosorter et le séquençage des génomes entiers. Nous avons également modifiés en profondeur le module ReFlx du cytomètre en flux adapté aux organismes de grande taille (COPAS Biosorter) afin d’éliminer les problèmes de contamination et diviser par sept le temps nécessaire au traitement dans le but de mener une étude de génétique inverse à haut débit par ARN interférence. Nous avons enfin générer des lignées fluorescentes bi-colores pour étudier la régulation dépendante de la région 3’ UTR grâce aux microARN. / The regulation of gene expression is fundamental to coordinate the synthesis, assembly and localization of macromolecular complexes in cells. This expression is regulated at various levels. It begins in the nucleus where transcription factors bind to specific DNA sequences and recruit RNA polymerases to synthesize RNA. Regulation at this level is called transcriptional. RNA binding proteins associate with RNA during synthesis and operate various modifications such as the addition of a 5' cap, splicing, editing and polyadenylation at the 3'. The transcripts are then exported to the cytoplasm where they will be sent to subcellular regions and stored. mRNA are then associated with translation factors and ribosomes to initiate protein synthesis in a controlled manner. Finally, mRNAs are degraded. Regulations that affect each of these steps are called post-transcriptional regulations. The recent tools developments for genomic scale analysis have allowed a better overall understanding of gene regulation programs at the transcriptional level. However, the overall architecture of systems that regulate post-transcriptional steps of gene expression is still misunderstood. Such a system of post-transcriptional regulation must be controlled by hundreds of RNA binding proteins and microRNA (miRNA) encoded in eukaryotic genomes. This is why it is important to have tools and platforms suited to the study of the post-transcriptional regulation on a genomic scale. During this thesis, we have focused our work on two post-transcriptional regulation programs in Caenorhabditis elegans : alternative splicing and miRNAs regulation. We used GFP and RFP double fluorescent alternative splicing reporter lines to study the architecture of this regulation and to identify trans factors and cis-elements by using forward genetics, random mutagenesis, automated screen through COPAS biosorter and whole genome sequencing. We also extensively modified the ReFlx module of the COPAS to fix carry over problems and divide by seven the time required for processing in order to conduct a High throughput reverse genetic study using RNA interference. We finally generate bi-color fluorescent lines to study 3 'UTR regulation mediated by microRNAs.

Le gène suppresseur de tumeurs TP53 exprime plusieurs isoformes, dont Δ40p53 (perte du domaine de transactivation) et Δ133p53 (perte du domaine de transactivation et d’une partie du domaine de liaison à l’ADN). Ces isoformes inhibent l’activité suppressive de p53 et seraient sur-exprimées dans les cancers (sein et mélanome). Dans les cancers faiblement associés à une mutation TP53, ces isoformes seraient de bons candidats pour inactiver p53. Il convient de comprendre les mécanismes transcriptionnels qui régulent leurs expressions. Δ133p53 est produite par un promoteur alternatif P3 localisé dans TP53. Nous avons montré que Δ133p53 est un gène cible de p53, qui transactive le promoteur P3 par fixation sur un élément de réponse présent dans l’exon 4. L’expression de Δ133p53 est corrélée à celle d’autres gènes cibles de p53 en réponse à un stress génotoxique. De plus, elle réprime la suppression de la prolifération induite par p53 en inhibant ses capacités de liaison à l’ADN. Δ40p53 est produite par épissage alternatif, dont la rétention de l’intron 2 favorise sa traduction et empêche celle de p53. Nous avons montré que des structures de type G-quadruplexes présentes dans l’intron 3 régulent l’exclusion de l’intron 2. Ces structures comprennent le polymorphisme TP53PIN3 (duplication de 16pb), qui change leur localisation et affecte l’expression des ARNm codant p53 et Δ40p53. De plus, nous avons montré que ce polymorphisme est associé à une accélération de la cancérogenèse dans le syndrome Li-Fraumeni, caractérisé par la présence d’une mutation germinale TP53 (effet modificateur: 19 ans de différence à l’âge moyen du premier diagnostique entre les deux variants). L’expression des isoformes de p53 dépend de mécanismes transcriptionnels différents, indiquant des rôles différents dans la modulation des fonctions suppressives de p53. En plus d’inactiver p53 dans les cancers, ces isoformes pourraient être à l’origine des effets modificateurs des polymorphismes de TP53 sur les mutants p53. / The TP53 tumour suppressor gene expresses several isoforms, of which Δ40p53 (lack of transactivation domain) and Δ133p53 (lack of both transactivation and part of DNA-binding domains). These isoforms inhibit p53 suppressive activity and have been shown to be over-expressed in cancers (breat and melanoma). In cancers associated with low TP53 mutation rate, these isoforms could be great candidates to inactivate p53. It seems important to understand the transcriptional mechanisms that regulate their expression. Δ133p53 is produced by an alternative P3 promoter within TP53. We showed that Δ133p53 is a p53 target gene. p53 transactivates the P3 promoter and interact with a response element within exon 4. Δ133p53 expression is correlated to other p53 target genes in response to genotoxic stress. In addition, Δ133p53 inhibits p53-dependent suppression of proliferation by inhibiting p53 DNA-binding activity. Δ40p53 is produced by alternative splicing: retention of intron 2 favours its translation while it avoid the one of p53. We showed that G-quadruplex structures are formed in intron 3 and regulate retention of intron 2. The TP53PIN3 polymorphism (16 bp duplication) is embedded within these structures and affects their locations leading to variation of mRNA expression of p53 and Δ40p53. In addition, we showed that this polymorphism is associated with acceleration of carcinogenesis in Li-Fraumeni syndrome, characterized by germline TP53 mutation (genetic modifier effect: difference of 19 years in mean age at first diagnosis of cancer between the two variants). The expression of p53 isoforms depends on different transcriptional mechanisms, suggesting different roles in the modulation of p53 suppressive functions. In addition to inactivate p53 in cancers, these isoforms could be the mediators of modifier effects observed for TP53 polymorphisms on mutant p53.

No description available.

No description available.

Τα τελικά προϊόντα προχωρημένης γλυκοζυλίωσης (AGEs: Advanced Glycation Endproducts) παίζουν σημαντικό ρόλο στην παθογένεια των διαβητικών αγγειακών επιπλοκών. Το καλύτερα χαρακτηριζόμενο είναι η N-καρβοξυμεθυλ-λυσίνη (CML). Τα AGEs προκαλούν σημαντικές επιδράσεις στα αγγεία με την πρόσδεσή τους σε ειδικούς υποδοχείς της κυτταρικής επιφάνειας, όπως τον RAGE (Receptor for Advanced Glycation Endproducts). Διαλυτές μορφές του RAGE (sRAGE) εμφανίζονται στο ανθρώπινο αίμα και δρουν ως παγίδα αιχμαλωτίζοντας τους φλεγμονώδεις προσδέτες του RAGE εξωκυττάρια, προστατεύοντας με αυτό τον τρόπο τα κύτταρα από τη βλάβη που προάγεται από τα AGEs. Σκοπός αυτής της εργασίας ήταν να μελετηθούν τα επίπεδα του sRAGE, η πρωτεϊνική έκφραση του RAGE, καθώς και τα επίπεδα CML σε σχέση με διάφορες κλινικές και βιοχημικές παραμέτρους σε παιδιά, εφήβους και νεαρούς ενήλικες με ΣΔ1. Τα επίπεδα sRAGE και CML προσδιορίστηκαν με ELISA και η πρωτεϊνική έκφραση του RAGE στα μονοπύρηνα του περιφερικού αίματος με ανοσοαποτύπωση κατά Western σε 74 παιδιά, εφήβους και νεαρούς ενήλικες με ΣΔ1 (13± 4 χρονών) και 43 μάρτυρες αντίστοιχης ηλικίας, φύλου και σταδίου Tanner. Σ’ αυτή την εργασία τα αυξημένα επίπεδα sRAGE στα παιδιά με ΣΔ1 και πιο ειδικά, σ’ αυτά ηλικίας κάτω από 13 ετών και με διάρκεια διαβήτη κάτω από 5 έτη, μπορεί να είναι ένα προσωρινό προστατευτικό μέτρο ενάντια στην κυτταρική βλάβη και πιθανόν να είναι επαρκές για να εξουδετερώσει επαρκώς τα κυκλοφορούντα CML, εμποδίζοντας έτσι τις διαβητικές αγγειακές επιπλοκές. Επίσης, μια ήπια αύξηση της LDL θα μπορούσε να είναι ένα ερέθισμα για την αύξηση του sRAGE, οδηγώντας στη δέσμευση του CML και τελικά τη μείωση των επιπέδων CML στην κυκλοφορία. Τα μειωμένα επίπεδα της πρωτεϊνικής έκφρασης του RAGE 55 kd (υποδοχέα πλήρους μήκους) μπορεί να αντανακλούν την αυξημένη έκφραση του sRAGE στους ασθενείς με ΣΔ1 συνολικά λόγω της αποκοπής του RAGE με μεταλλοπρωτεϊνάσες. Με την παρουσία κάποιου παράγοντα κινδύνου, όπως αύξηση ηλικίας, περιμέτρου κοιλίας, BMI, συστολικής ή διαστολικής αρτηριακής πίεσης ή επιδείνωση λιπιδαιμικού προφίλ αυξάνεται η πρωτεϊνική έκφραση της ισομορφής αυτής, ενώ φαίνεται αντίστοιχα να μειώνονται τα επίπεδα του sRAGE. Φαίνεται τελικά ότι συνολικά στα παιδιά, τους εφήβους και τους νεαρούς ενήλικες με ΣΔ1 υπάρχει μια υποκλινική διαταραχή του άξονα sRAGE-RAGE-CML, η οποία δύναται να μετατραπεί σε κλινικά εμφανείς αγγειακές βλάβες, αν προστεθούν περαιτέρω επιβαρυντικοί παράγοντες. / The binding of Advanced Glycation Endproducts (AGEs) to their receptor (RAGE) plays a major role in the development of diabetic vascular complications. This work is based on the relation between circulating soluble RAGE (sRAGE) levels in children, adolescents and young adults with IDDM and RAGE protein expression in association with N-(carboxymethyl)lysine (CML), a major antigenic AGEs component. Circulating sRAGE and CML levels were determined by ELISA and RAGE protein expression was evaluated in peripheral blood mononuclear cells by western immunoblotting in 74 children, adolescents and young adults with IDDM (134 years old) and 43 age, sex and Tanner stage-matched controls. Serum sRAGE levels were significantly higher in IDDM than in controls, inversely correlated to diabetes duration and directly correlated to LDL levels. Furthermore, circulating CML levels were not significantly different between IDDM and controls. Also, the protein expression of the RAGE isoforms 55 kd (full-length), 64 kd and 100 kd, measured by western immunoblotting, was significantly lower in IDDM than in controls, whereas RAGE 37 kd levels were not significantly different between IDDM and controls. Finally, when there was a risk factor, such as increased age, poor lipid profile, increased BMI or waist circumference or increased systolic or diastolic pressure, then it seemed that isoforms RAGE 55, 64 and 100 kd were increased. Isoform RAGE 64 kd could be RAGE-v5, a splice variant which resulted in a change of amino acid sequence in the extracellular ligand-binding domain of RAGE. Isoform RAGE 37 kd seemed to be Δ8-RAGE, a soluble splice variant with probably protective function, which had been found increased in patients with increased HDL. Finally, isoform RAGE 100 kd seemed to be some other splice variant in peripheral mononuclear cells. In conclusion, increased serum levels of sRAGE seen in IDDM children may be a temporary protective measure against cell damage and may be sufficient to efficiently eliminate excessive circulating CML. Moreover, the lower protein expression of the full-length RAGE in IDDM may also reflect the increased sRAGE expression in patients due to RAGE cleavage by metalloproteases. Consequently, in IDDM children, adolescents and young adults there may be a subclinical perturbation of the sRAGE-RAGE-CML axis, which could lead to future clinical vascular damage if additional risk factors are added over time.

Pre-mRNA splicing is an important level in posttranscriptional gene regulation that is essential for accurate protein synthesis and generating protein diversity. The abundance of cryptic splice sites and long intronic DNA sequences makes their splicing a complex one. The identification of correct exons and introns needs additional information in the form of splicing regulatory elements (SREs) along with canonical splice signals. The interplay among these SREs and the trans factors (which bind to SREs) gives the identity to introns and exons which in turn leads to precise pre-mRNA splicing. Previous studies from our laboratory showed, that when expressed in mammalian cells from an expression vector, PDGF-B ORF was re-spliced at 4/5 exon junction with the downstream SV40 splice acceptor site in the vector. However, deletion of the 66-nt PDGF-B 3’ UTR region resulted in about 25% reduction in re-splicing. Sequence analysis of this region revealed presence of binding sites for splicing factors ASF/SF2 and SRp55, and an AU-rich element (ARE), mutation each of which affected re-splicing partially. In mammals, AREs are commonly found in the 3’UTR of mRNAs encoding proteins involved in diverse functions and are involved in selective mRNA degradation. Several ARE binding proteins are crucial for ARE’s function. Since mutation of the single ARE in the 3’UTR region altered the re-splicing efficiency, the role of AU-rich elements and ARE-binding proteins (AU-BPs) in modulation of splicing was investigated using siRNAs against AU-BPs, BRF1, hnRNPD, HuR, GAPDH and TTP. Down regulation of expression of these factors indeed affected the level of re-spliced product. We have studied the interactions between the full-length splicing factors (U1-70K and U2AF35) and the AU-BPs (BRF1, hnRNPD and HuR) as well as among the AU-BPs using three different assay methods: Yeast-two hybrid, co-immunoprecipitation and pull down assays. Our study has revealed that the BRF1 interacts with U1-70K and U2AF35 as well as the other AU-BPs hnRNPD and HuR but with different affinities. We have also analyzed the ability of AU-BPs to interact with SR proteins SRp20 and 9G8. We did find strong interaction of BRF1 with SRp20 and 9G8. Generation of a large number of nested deletion mutants of all the proteins allowed us to identify the interaction regions on the surface of BRF1, U1-70K, hnRNPD, U2AF35 and HuR. The results of Y2H analyses were further confirmed by pull down assay using purified interacting regions. It was found that a single region from aa 181-254 in BRF1 interacts with multiple partners i.e., splicing factors and the AU-BP hnRNPD. However, the RNA-binding zinc-finger domain from residue 120-181 independently interacts with HuR. Further, the multiple protein interacting region (MPIR) (aa 181-254) in BRF1 exhibits different affinities towards its interacting partners with that for U1-70K and hnRNPD being stronger than that for U2AF35 and HuR. This observation suggests that BRF1 activity can be modulated by interaction with different partners at different sites. U1-70K interacted only with BRF1 among the proteins tested in this study and this interaction appears to be RNA independent .This could have implications in splice site selection and RNA stability since BRF1 has been shown to promote RNA degradation. While the Arg/Glu-rich C-terminal region in U1-70K is sufficient for its interaction with BRF1, U2AF35 requires both the zinc-finger 2 and the arg/Gly/Ser-rich C-terminal regions for its association with BRF1. hnRNPD also interacts with multiple partners that include BRF1, HuR and U2AF35 using the N-terminal region that harbors a Ala-rich domain. The interaction of hnRNPD with HuR is RNA dependent while with BRF1 and U2AF35, it is RNA independentt. Further, its interaction with all the partners is equally strong. This suggests that hnRNPD could exert differential influence depending on the context of its interaction and abundance of the interacting partner. HuR, primarily known as an mRNA stabilizing factor, interacts with both BRF1 and hnRNPD with equal affinity involving the hinge region, the interaction with the former being RNA-independent and the later being RNA-dependent. This differential RNA-dependent and independent interactions with the two AU-BPs using a single interacting domain suggests a balancing act of HuR on the activities of BRF1 and hnRNPD. These interactions can further be differentially modulated by posttranslational modifications on one or all of the interacting partners depending on the physiological status of the cell. We have also analyzed the multiple protein complexes formed in absence of cellular RNA. Though we are unable to see direct protein-protein interaction between HuR and U1-70K in Yeast two hybrid analysis, we could detect the presence of U1-70K in HuR immunoprecipitate. It appears that U1-70K associates with HuR via BRF. We also detected the presence of HuR in U1-70K complexes which could be due to its association with BRF1. We are unable to find hnRNPD and U2AF35 in these complexes indicating that they may have been excluded. In anti-U2AF35 immunoprecipitates, we detected the presence of U1-70K as well as hnRNPD but no HuR. This may be due to RNase treatment as hnRNPD and HuR interactions are RNA dependent. Our findings that AU-rich elements in conjunction with AU-BPs function as intronic splicing modulators or enhancers, reveal hitherto unidentified new players in the poorly understood complex mechanisms that mediate alternative splicing. The possibility of dynamic nature of the interactions among splicing factors and AU-BPs mediated by post-translational modifications provide a basis for rapid cellular responses to changing environmental cues through generation of differentially spliced mRNAs and corresponding protein products that differ in their stability and hence their relative abundance. Our results also unfold enormous possibilities for future investigations on interactions among the many splicing factors and AU-BPs, and in understanding these complex interactions in modulation of pre-mRNA splicing, mRNA translation and degradation. The finding of coupling of AU-BPs to splicing machinery could further lead to better understanding of the mechanism of AU-BP-mediated targeting of mRNAs to processing bodies and ultimate degradation of the mRNAs.